HealthValue
Chromosome 5

Chromosomes have a long arm (q) and a short arm (p)
To distinguish various segments of the arms, they are divided, by nomenclature, into "bands" that correspond to histological staining. Hence 5q 31.1 means "short arm of chromosome 5, band 31, sub-band 1".
Loss of part of a chromosome is called a "deletion". 
Nearly 100 hereditary or acquired diseases correspond to anomalies of chromosome 5 (to see them all, click )
5q deletions are frequent in malignant myeloid disorders :

  - some acute myeloid leukemias
  - some myelodysplastic syndromes (MDS):

"The 5q syndrome is a milder form of myelodysplasia in which refractory anemia is the predominant clinical feature. The fundamental deletion in these 5q MDS includes bands q31-q33. Overall median survival is 107 months" (see Giagounidis 2004)
However when a 5q.31deletion is associated with complex chromosomal abnormalities, median survival is 7 to 8 months (see Giagounidis 2005)
- abatacept
- basiliximab
- belatacept
- bevacizumab
- cetuximab
- dacluzimab
- eculizumab
- mapatumumab
- ocrelizumab
- panitumumab
- rituximab

Information on monoclonals
Information on VEGF antagonists :

- Bevacizumab
- Sunitinib
- Sorafenib
Lenalidomide was approved by the FDA on December 27, 2005, for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk* myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
* see explanation of scoring system
Other cancer related issues :
back to home page
Promenade guidée, suite
MONOCLONALS
abatacept
abciximab
adalimumab
alefacept
alemtuzumab
anti KDR
basiliximab
belatacept
bevacizumab
CDP 791
cetuximab
dacluzimab
denosumab
eculizumab
efalizumab
etanercept
IMC 1121
infliximab
ipilimumab
lumiliximab
Mab 806
mapatumumab
matuzumab
natalizumab
nimotuzumab
ocrelizumab
ofatumumab
omalizumab
palivizumab
panitumumab
ranibizumab
rituximab
ticilimumab
trastuzumab
VEGF Trap
zalutumumab
ABOUT MONOCLONALS
what is a monoclonal
chains & fragments
therapeutic fields
what are CDs
types of monoclonals
fusion proteins
cells to build monoclonals
making monoclonals
IgG1/IgG2 differences
F(ab) fragments
Fc fragment
Fc structure
Fc e receptors
BioTherapies
antisense
cell therapy
exon skipping
gene therapy
hemopoietic prog.
monoclonals
protein kinases
recombinant prot.
stem cells
Cells/organelles
cell cycle
cells
chromosomes
DNA repair
exons
hemopoietic prog.
introns
lysosomes
mb. receptors
membrane CDs
mitochondria
proteasomes
stem cells
DISEASES
bird flu
cancer
diabetes
human growth hormone diseases
lysosomal diseases
mitochondrial diseases
multiple sclerosis
myelodysplastic sd
myopathies
osteoporosis
paroxysmal nocturnal hemoglobinuria
psoriasis
Pathways
Adams
AKT
amino acids
complement
cancer pathways
cdk
DPP IV
EGF
EGFRvIII
GPCR
G proteins
ILGF
kinome
Kras
mannose P
NFKB
nucleotides
protein kinases
proteins
Ras
RET
sheddases
sunitinib/sorafenib
VEGF
Wnt